semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ductal Breast Carcinoma in Situ Core needle biopsy demonstrating DCIS (ductal carcinoma in situ) of non-palpable, image-detected breast abnormality Mammographic or MRI non-mass lesion (calcifications, non-mass enhancement on MRI) measuring 3 cm or less in greatest dimension Estrogen receptor positive or negative, progesterone receptor positive or negative; HER2 positive or negative DCIS Diagnostic needle biopsy within 16 weeks of randomization Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging and evidence of residual radiographic abnormality. The post-biopsy mammogram must be performed within 6 weeks of randomization date Placement of Savi scout optical reflectance marker for contouring of tumor bed area for partial breast irradiation treatment planning via mammography, CT, or MRI and for image-guiding of surgery Planned lumpectomy. Mastectomy will be acceptable if lumpectomy fails by virtue of involved margins or size of lesion, or patient chooses this approach Evaluation by Radiation Oncologist to ascertain feasibility of PBI prior to randomization. Planned breast irradiation should encompass less than 30% of the breast volume Patients who had a prior contralateral invasive or non-invasive (DCIS) cancer are eligible Eastern cooperative oncology group (ECOG) performance status 0, 1, or 2  Invasive carcinoma on core needle biopsy, including microinvasive carcinoma Radiographic extent of DCIS >3.0 cm Mass lesion on breast imaging or palpable tumor No residual radiographic lesion after diagnostic percutaneous core needle biopsy Prior history of ipsilateral invasive or noninvasive breast cancer Pregnant or breastfeeding Prior ipsilateral breast or chest irradiation Multicentric or multifocal DCIS Synchronous contralateral invasive or non-invasive breast cancer Pagets' disease of the breast
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Ability to comply with the study protocol, in the investigator's judgment Histologically confirmed invasive breast carcinoma, with all of the following characteristics: Primary tumor greater than or equal to (≥)1.5 centimeters (cm) in largest diameter by ultrasound; Stage I-III operable breast cancer; Documentation confirming the absence of distant metastasis (M0) as determined by institutional practice ER-positive tumor and HER2-negative breast cancer as per local laboratory testing Postmenopausal status Breast cancer eligible for primary surgery Submission of a representative tumor tissue specimen Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to (≤)1 Adequate organ function  Diagnosis of inflammatory breast cancer Diagnosis of bilateral breast cancer Concurrent use of hormone replacement therapies Previous systemic or local treatment for the primary breast cancer currently under investigation Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study entry Current treatment with any systemic anti-cancer therapies Major surgery within 4 weeks prior to enrollment Radiation therapy within 2 weeks prior to enrollment Diagnosis of any secondary malignancy within 3 years prior to enrollment, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 51.0-999.0,  Breast Cancer Female Hormone Receptor Positive Tumor for Prosigna® screening Diagnosis of invasive breast cancer which is Unifocal or multifocal (not multicentric) Unilateral Moderate or strongly hormone receptor positive HER2 negative Ductal grade 1 or 2, or lobular any grade, or pure tubular (any grade) or pure papillary (any grade). If mixed lobular-ductal histology, the ductal component must be grade 1 or 2 Stage pT1N0 (tumor </= 20mm, negative node) or pT2N0 (tumor 21-50mm, node negative) or pT1N0i+ (tumor </=20mm and isolated tumor cells in node[s]) or pT2N0i+ (tumor 21-50mm and isolated tumor cells in node[s]) (see Appendix 2). Tumor size must be sufficient for Prosigna® testing. pNX (nodal status unknown) stage is not eligible Subject must be female Subject must be age > 50 years at breast cancer diagnosis  • Does not meet every listed above
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Breast Tissue Neoplasm Patients with pathologically confirmed invasive ductal carcinoma (Grade 2 or 3) Undergoing wide local excision surgery or mastectomy  Started hormone or chemotherapy treatment before recruitment Undergoing treatment for concurrent cancer diagnosis Taking antibiotics, proton pump or vegetable dietary supplement
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 45.0-45.0,  Early Stage Breast Cancer Patients with stage 0, I, or II (Tis, Ti, or T2 <=3cm & NO) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm, treated with wide excision Negative inked histologic margins of excision or reexcision and clear of invasive tumor and DClS by at least 2mm Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before radiotherapy No involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection Enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment  Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy Patients who are pregnant Patients who have any histologically confirmed positive axillary nodes Patients with collagen vascular diseases, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis with a creatine phosphokinase level above normal or with an active skin rash
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Biliary Stricture Pancreas Cancer Cholangiocarcinoma Bile Duct Cancer Bile Duct Neoplasms Malignant Bile Duct Neoplasms Bile Duct Lesions Bile Duct Obstruction Bile Duct Diseases Bile Duct Obstruction, Extrahepatic Bile Duct Stenosi Bile Duct Adenoma Pancreatic Duct Stricture Pancreatic Duct Stenosis Pancreatic Duct Obstruction Pancreatic Ductal Adenocarcinoma Primary Sclerosing Cholangitis VLE clips featuring indeterminate biliary or pancreatic duct stricture with confirmed diagnosis on pathology -
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer cT1-4c (multifocality / multicentricity permitted) Female / male patient aged ≥ 18 years cN+ based on the following (at least one must be met) lymph node is palpable cortical asymmetry (focal or diffuse cortical thickening of >3mm) under US cortex:hilum ratio >2:1 under US loss of hilum/cortex structure under US Written informed consent (ICF)  Suspicious lymph nodes after neoadjuvant therapy No confirmed breast cancer and no abnormality in the breast Patient uses Marcumar Pregnant and lactating women Known hypersensitivity reaction against local anesthesia Prior chemo or radiation therapy in breast or axilla Missing written informed consent
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  TN ER-/PR-/HER2- Breast Cancer Triple Negative Breast Cancer HER2-positive Breast Cancer ERany/PRany/HER2+ Breast Cancer Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned A biopsy clip placed at the time of diagnostic biopsy years of age or older Must be able to read and write in English due to the importance of survey (questionnaire) completion to meet the study's endpoint this is justified as there is no individual benefit to study participation Able to provide written consent prior to any research related activities  Stage IV breast cancer T4 breast cancer Previous ipsilateral breast cancer Any contraindication for undergoing a contrast-enhanced breast MRI and/or the breast biopsy between chemotherapy and surgery
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women with newly diagnosed human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor (ER) positive or negative, progesterone receptor (PR) positive or negative infiltrating ductal carcinoma (IDC) of the breast Clinically stage II-III Patients with inflammatory, multifocal, multicentric and synchronous bilateral breast cancers are allowed. However, in patients with inflammatory breast cancer, patients must have a measurable, biopsied mass within the breast pre-chemotherapy Willing and able to provide informed consent Age ≥ 18 years Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1 Patients must be able to receive neoadjuvant anthracycline / taxane based chemotherapy in the opinion of the treating physician Adequate bone marrow function, as defined by peripheral granulocyte count of ≥ 1,500/mm3, and platelet count ≥100,000/mm3 Adequate renal function with creatinine levels ≤ 1.5 X the upper limit of normal and estimated glomerular filtration rate (eGFR) >30 Adequate liver function with a bilirubin, Alkaline phosphatase and transaminases (ALT and AST) of ≤ 1.5 X the institutional upper limit of normal  Patients must not have had surgery or radiation or begun chemotherapy or endocrine therapy for their breast cancer prior to registration Patients must not be pregnant or nursing due to the possibility of harm to a fetus or nursing infant from this treatment regimen Presence of electrically, magnetically, or mechanically activated implants including cardiac pacemakers, cochlear implants, magnetic surgical clips or prosthesis that would preclude MRI History of severe claustrophobia History of allergic reaction to gadolinium Patients must not have metastatic disease Baseline sensory/motor neuropathy > grade 2 Clinically significant cardiovascular disease Serious intercurrent infection or nonmalignant medical illness Creatinine clearance prohibiting the use of gadolinium (eGFR < 30)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Breast Cancer Histological diagnosis of breast cancer, availability of primary tumor tissue and plasma DNA with a high ctDNA content  Patient rejects the participation
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer Female Age18-70 years Imaging examination confirmed single lesion. if the tumor is multiple, it needs to be removed by single quadrantectomy Receive breast conserving surgery with negative margins Axillary lymph nodes treatment: Sentinel lymph node biopsy or level I/II axillary lymph node dissection. If the sentinel lymph node is negative, the axillary lymph node dissection can be omitted. If it is positive, level I/II axillary lymph node dissection with or more than 10 lymph nodes is needed The tumor bed is labeled with clips and it can be drawn on the treatment planning system Pathologically confirmed invasive breast cancer Pathologically stage is T1-3N0-3M0 Immunohistochemical examination is conducted to determine the status of ER, PR, HER2, Ki67 after surgery No distant metastases  T4 or M1 breast cancer Supraclavicular or internal mammary nodes metastases Pathologically confirmed DCIS only without an invasive component Bilateral breast cancer or historically confirmed contralateral invasive breast cancer Treated with neoadjuvant chemotherapy or neoadjuvant endocrine therapy Multiple lesions can not be removed by single quadrantectomy Suspicious unresected and microcalcification, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) KPS ≤ 70 Patients with severe non-malignant comorbidity in cardiovascular or respiration system Concurrent or previous malignancy excluding basal or squamous cell carcinoma of the skin
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer HER2-positive Breast Cancer Women aged 18-75 years old; HR positive and HER2 positive (immunohistochemistry or FISH test confirmed). 2. ECOG score ≤ 2, expected survival ≥ 3 months. 3. Histology or cytology confirmed as breast cancer. 4. Prior to trastuzumab and endocrine therapy and progression/recurrence. 5. At least one 1.1 defined measurable lesions. 6. Normal function of major organs  pregnant or lactating women 2. Patients who have relapsed or progressed within 12 months of end of adjuvant or neoadjuvant therapy, including chemotherapy, target therapy (eg lapatinib， trastuzumab), or other anti-tumor therapy. Except for endocrine therapy. 3. Severe chronic gastrointestinal diseases with diarrhea as the main symptom (such as Crohn's disease, malabsorption, or ≥2 grade diarrhea caused by any cause at baseline). 4. Rapid progress of organ invasion (such as liver and lung disease greater than 1/2 organ area or liver dysfunction, etc.) 5. Patients with central nervous system disorders or mental disorders 6. Bone metastasis lesions only, no other measurable lesions. 7. Hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg) without ideal control. 8. Uncontrolled heart disease. 9. Have congenital long or short QT syndrome or have a family history or personal history of Brugada syndrome. 10. Uncontrolled rain metastasis
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Node-positive Breast Cancer Node-positive breast cancer patients confirmed by biopsy or cytology Positivity confirmed before the surgical treatment  Inability to confirm positive lymph nodes by biopsy or cytology Inability to understand the protocol design Poor understanding of the Spanish language
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer Patients with histological and imaging findings-confirmed hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer postmenopausal patients eligible patients receiving one or more treatment strategies who are followed up in the center where they receive treatment provision of written informed consent  Age < 18 years pregnant woman participating in other clinical trials
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Breast Neoplasms estrogen receptor (≥ 10%), progesterone receptor (≥ 10%) and epidermal growth factor receptor 2 negative proliferation index Ki-67 < 14% no lymph node metastasis systemic therapy (chemotherapy, radiotherapy and endocrine therapy) in accordance with the National Comprehensive Cancer Network guidelines provision of informed consent of patients and their families  Bilateral breast cancer inflammatory breast cancer pregnancy or lactation history of other cancers or chest radiotherapy